Thyroid: biological actions of ‘nonclassical’ thyroid hormones

Rosalba Senese*, Federica Cioffi¹*, Pieter de Lange, Fernando Goglia¹ and Antonia Lanni

Dipartimento di Scienze e Tecnologie Ambientali, Biologiche e Farmaceutiche, Seconda Università degli Studi di Napoli, Via Vivaldi 43, 81100 Caserta, Italy

¹Dipartimento di Scienze e Tecnologie, Università degli Studi del Sannio, Via Port'Arsa 11, 82100 Benevento, Italy

*(R Senese and F Cioffi contributed equally to this work)

Correspondence should be addressed to A Lanni
Email
antonia.lanni@unina2.it

Abstract

Thyroid hormones (THs) are produced by the thyroid gland and converted in peripheral organs by deiodinases. THs regulate cell functions through two distinct mechanisms: genomic (nuclear) and nongenomic (non-nuclear). Many TH effects are mediated by the genomic pathway – a mechanism that requires TH activation of nuclear thyroid hormone receptors. The overall nongenomic processes, emerging as important accessory mechanisms in TH actions, have been observed at the plasma membrane, in the cytoplasm and cytoskeleton, and in organelles. Some products of peripheral TH metabolism (besides triiodo-L-thyronine), now termed ‘nonclassical THs’, were previously considered as inactive breakdown products. However, several reports have recently shown that they may have relevant biological effects. The recent accumulation of knowledge on how classical and nonclassical THs modulate the activity of membrane receptors, components of the mitochondrial respiratory chain, kinases and deacetylases, opened the door to the discovery of new pathways through which they act. We reviewed the current state-of-the-art on the actions of the nonclassical THs, discussing the role that these endogenous TH metabolites may have in the modulation of thyroid-related effects in organisms with differing complexity, ranging from nonmammals to humans.

Key Words

- thyroid hormone
- nongenomic effects
- thyroid hormone metabolism
- thyroid hormone receptors

Journal of Endocrinology
(2014) 221, R1–R12

Introduction

General notions

The thyroid gland produces two main iodothyronines: tetraiodo-L-thyronine (T₄) and triiodo-L-thyronine (T₃). In humans, T₄ is synthesized entirely within the thyroid and acts as a pro-hormone to generate T₃. Only 20% of the T₃ in circulation is secreted directly by the gland itself. The remaining T₃ derives from the peripheral monodeiodination of T₄. Deiodinase activity regulates the local and systemic availability of T₃ and other iodothyronines. Thyroid hormone (TH) deiodination is mediated by three

selenoenzymes: type 1 deiodinase (D1), preferentially expressed in the liver and also expressed in the kidney, thyroid, and pituitary; D2, present in the CNS, anterior pituitary, brown adipose tissue, and placenta; and D3 in the CNS, placenta, skin, and fetal tissue. For further details on deiodinases, the reader is referred to Bianco (2011), Maia *et al.* (2011), Orozco *et al.* (2012) and Luongo *et al.* (2013).

Other biochemical pathways are involved in TH metabolism in addition to deiodination. Conjugation of phenolic hydroxyl groups with sulfate or glucuronic acid

increases water solubility of substrates, facilitating biliary and/or urinary clearance (Visser 1990). Decarboxylation and deamination of THs lead to the formation of the so-called acetic acid-TH analogs such as triiodothyroacetic (Triac) and tetraiodothyroacetic (Tetrac) acids (Siegrist-Kaiser & Burger 1994). Several transporters contribute to the uptake of TH into the peripheral tissue, including organic anion-transporting polypeptides (OATPs), L-type amino acid transporters, monocarboxylate transporters (MCT), and bile acid transporters see for a recent review: Visser (2013).

TH actions

THs regulate cell functions through two distinct mechanisms: genomic (nuclear) and nongenomic (non-nuclear). Most effects of TH are mediated by the genomic pathway – a mechanism that requires thyroid hormone activation of nuclear receptors (TRs). This leads to a conformational change allowing interaction with specific thyroid hormone responsive elements located on the promoters of THs target genes (Bassett *et al.* 2003, Moeller & Broecker-Preuss 2011, Tata 2013, Pascual & Aranda 2013), regulating transcription rate. TRs homodimerize or interact with other nuclear receptors such as the retinoic X receptor (Forman *et al.* 1992, Bogazzi *et al.* 1994). TRs belong to a large family of ligand-dependent transcription factors, which includes nuclear hormone receptors for vitamins, xenobiotics, and sex steroids (Weitzel & Alexander Iwen 2011). They are termed as TR α and TR β and are encoded by two genes (α and β) located on two different chromosomes (Cheng 2000) that express differently in developing and adult tissues (Oetting & Yen 2007, Cheng *et al.* 2010). Highest *Tr α 1* (*Thra*) expression is in the brain, with lower levels in the kidney, skeletal muscle, lungs, heart, and liver, whereas *Tr β 1* is expressed predominantly in the kidneys and liver, and at lower levels in the brain, heart, thyroid skeletal muscle, lungs, and spleen (Williams 2000). TR β isoforms are involved in lipid metabolism (Pramfalk *et al.* 2011) by reducing serum lipids (Johansson *et al.* 2005, Angelin & Rudling 2010, Shoemaker *et al.* 2012). TR β disruption in mice impairs fatty acid (FA) oxidation (Araki *et al.* 2009) even in the presence of TR α over-expression (Gullberg *et al.* 2000, 2002). TR β agonists have approximately tenfold greater affinity for TR β than TR α , with a marked effect on the liver and efficacy in lowering of cholesterol (Webb 2010, Ladenson 2011). Although T₃ exerts many of its actions through canonical transcriptional regulation, an increasing amount of evidence shows that many of T₃ effects are initiated outside the nucleus and

involve different signaling transduction pathways. These effects are mediated by nongenomic actions. The overall nongenomic processes are poorly understood but emerge as important accessory mechanisms in TH actions and have been observed at the plasma membrane, in the cytoplasm and cytoskeleton, and in organelles (Wrutniak-Cabello *et al.* 2001, Cheng *et al.* 2010). Membrane receptors, consisting of specific integrin α V β 3 (α V β 3) receptors, have been identified (Bergh *et al.* 2005). THs on the cell surface trigger the serine–threonine kinase (MPK/ERK) pathway via the integrin receptor (Bergh *et al.* 2005, Cody *et al.* 2007), initiating complex cellular events (Lin *et al.* 2009a,b). In the cytoplasm, THs activate PI3K and thereby downstream gene transcription of specific genes. T₃ also activates PI3K from the integrin α V β 3 hormone receptor site (Lin *et al.* 2009b, Moeller & Broecker-Preuss 2011). Calcium is a second messenger regulated by THs through the modulation of a Ca²⁺-ATPase (Galo *et al.* 1981). Del Viscovo *et al.* (2012) showed that THs exert short-term nongenomic effects on intracellular calcium by modulating plasma membrane and mitochondrial pathways in rat pituitary GH3 cells. Furthermore, cellular actions involving Akt/protein kinase B (shown in human fibroblasts; Moeller *et al.* 2005) and AMP-activated protein kinase (AMPK) (in mice) (Irrcher *et al.* 2008) are well known. De Lange *et al.* (2008) showed that in rat skeletal muscle, T₃ stimulates FA and glucose metabolism through rapid activation of AMPK and Akt/protein kinase B signal transduction.

THs regulates mitochondrial activity and thus it may perhaps not be surprising that the mitochondria themselves are important target for THs. THs modulate mitochondrial activity through two ways: direct or indirect. The first requires the presence inside the organelles of specific binding sites for THs that play important physiological roles in regulation of the mitochondrial transcription apparatus (see for review, Cioffi *et al.* (2013)). One of these binding sites, termed p43, has been identified as a bona fide TR that binds to the D-loop region that contains the promoters of the mitochondrial genome (Wrutniak *et al.* 1995). By contrast, the indirect way acts through increased, nuclear TR-dependent transcription of factors that modulate the expression of mitochondrial genes (see for review, Cioffi *et al.* (2013)).

The nonclassical THs

Besides T₃, nonclassical THs exist. In the present review, we summarize the highlights of their biological actions.

Tetrac and Triac

In humans, the amount of Triac produced by the liver and other tissues accounts for about 14% of T_3 metabolism (Siegrist-Kaiser & Burger 1994). Triac is weakly $TR\beta$ -selective, with a 1.5-fold affinity for $TR\beta$ (Schueler *et al.* 1990). Triac has been used to suppress thyroid-stimulating hormone (TSH) secretion in TH-resistant patients (Kunitake *et al.* 1989) and to increase metabolic rate in obese patients (Dumas *et al.* 1982). It has been shown to be more potent than T_3 as both a β -adrenergic stimulator of uncoupling protein 1 and inducer of lipoprotein lipase mRNA, D3 activity, and mRNA (Medina-Gomez *et al.* 2003). Triac inhibits expression and secretion of leptin in rat primary white and brown adipocytes with a potency similar to that of T_3 (Medina-Gomez *et al.* 2004). The use of Tetrac as a potential substitute for T_4 has been studied in the treatment of myxedema and for its ameliorating effect on peripheral lipid metabolism in humans. The effects are similar to those of T_4 , but require higher dosing (Lerman 1956). Tetrac is currently used in the clinic for the treatment of TH resistance (Anzai *et al.* 2012). Therapeutic doses of Triac to treat pituitary and thyroid disorders exceed those required for T_4 and T_3 (Sherman & Ladenson 1992, Bracco *et al.* 1993), a property attributed to its short half-life in humans and rodents (Pittman *et al.* 1980, Moreno *et al.* 1994). Classic THs are transported within the cell by TH transporters (Visser 2013). Tetrac does not seem to depend on active transport, at least by the most abundant transporter MCT8. Tetrac can replace T_3 to restore normal fetal mouse brain development in MCT8-null mice (Horn *et al.* 2013).

Thyronamines

The structures of the thyronamines (TAMs), a novel class of endogenous thyroid-signaling molecules, differ from T_4 and deiodinated TH derivatives by the absence of a carboxylate group on the alanine side chain. 3-Iodothyronamine (T1AM) and TOAM have been detected *in vivo* (Scanlan *et al.* 2004, DeBarber *et al.* 2008) in the serum of rodents and humans (Saba *et al.* 2010, Hoefig *et al.* 2011), in rat liver, brain, and heart (Chiellini *et al.* 2007, Saba *et al.* 2010). Data from Piehl *et al.* (2008) present a role for deiodinases in TAM biosynthesis, defining biosynthetic pathways for T1AM and TOAM with T_4 as a pro-hormone. Seemingly in contrast, a recently developed method to detect T1AM and TOAM in tissues and plasma (Ackermans *et al.* 2010) failed to reproduce the above data. Using rats treated with (13)C-labeled T_4 , the authors could detect

in vivo conversion of T_4 to T_3 but not to T1AM in plasma or brain samples, neither any endogenous T1AM nor TOAM was detected in the plasma from rats and plasma and in thyroid tissue from humans. Indeed, iodothyronine decarboxylation to iodothyronamines has not been demonstrated directly, and the aromatic amino acid decarboxylase was shown to be unable to catalyze iodothyronine decarboxylation (Hoefig *et al.* 2012). In line with this, data from Hackenmueller *et al.* (2012) suggest that T1AM is not an extrathyroidal metabolite of T_4 , yet is produced within the thyroid by a process that requires a sodium–iodide symporter and thyroperoxidase, the same biosynthetic factors necessary for T_4 synthesis. These data shed new light on the pathways potentially involved in T1AM production and imply that the enzymatic conversion of iodothyronine to iodothyronamine is not simple. Steady-state physiological T1AM serum concentrations are similar to those of T_3 , and tissue concentrations of its metabolite, TOAM, exceed T_4 and T_3 metabolites by two- and 20-fold respectively (Hart *et al.* 2006, Chiellini *et al.* 2007). Physiological receptor(s) of TAMs remain to be identified. In TR receptor binding/gene activation assays, T1AM showed no affinity for $TR\beta$ and $TR\alpha$, and inability to modulate nuclear TR-mediated transactivation (Chiellini *et al.* 1998). Studies surrounding TAM association with other receptors concluded that neither TOAM nor 3-T1AM activated G α s-coupled dopamine D1 and β_2 adrenergic receptors (Scanlan *et al.* 2004). T1AM, however, was found to be a potent agonist of trace amine-associated receptor 1 (TAAR1), an orphan G protein-coupled receptor (Zucchi *et al.* 2006). Rat and mouse TAAR1 are activated by T1AM, with EC₅₀ values of 14 and 112 nM respectively. The T1AM ligand pharmacophore that activates TAAR1 was later characterized (Hart *et al.* 2006, Tan *et al.* 2007, 2008, Snead *et al.* 2008). T1AM reduces activation of the proto-oncogene *c-fos* (Manni *et al.* 2012). Ianculescu *et al.* (2009) reported that the cellular uptake of T1AM occurs via specific, saturable, and inhibitable transport mechanisms that are sodium and chloride independent, pH dependent, TAM specific, and do not involve candidate transporters of monoamines, organic cations, or THs. By a novel RNAi screening method, eight transporters of interest were identified. Knockdown resulted in T1AM transport in HeLa cells, but the physiological role of these transporters remains unknown. Studies using COS-1 cells transfected with multispecific OATPs, 1A2, 1B3, and 1C1, and the specific TH transporters, MCT8 and MCT10, proved that T1AM differentially inhibits T_3 and T_4 cellular uptake by these transporters (Ianculescu *et al.* 2010). Notably, T1AM

also inhibits both T_3 and T_4 uptake via MCT8, the most specific TH transporter. T1AM has no effect on TH transport by OATP1B3 and MCT10.

In mice, [Scanlan *et al.* \(2004\)](#) showed that a single i.p. injection of T1AM rapidly induced an $\sim 10^\circ\text{C}$ drop in body temperature that peaked 1 h after injection and dose dependently disappeared after 4–6 h. The same authors further showed that T1AM reduction on cardiac performance was a direct effect and independent of T1AM-induced hypothermia. In a rat working heart preparation held at 37°C , introduction of T1AM into the perfusion buffer resulted in large and immediate decreases in both heart rate and systolic aortic pressure. Additional studies on the heart have further supported direct actions of T1AM on this organ ([Chiellini *et al.* 2007](#), [Frascarelli *et al.* 2008](#)). A single i.p. dose of T1AM dramatically switched fuel utilization away from carbohydrates and toward lipids ([Braulke *et al.* 2008](#)). Siberian hamsters (*Phodopus sungorus*), a hibernating rodent species, and mice completely shifted their respiratory quotients (RQ) from a normal, mixed carbohydrate and lipid value (0.90 for hamsters and 0.83 for mice) to a complete and persistent lipid-related RQ value of ~ 0.7 with elevated urine ketone content. The RQ effect (4.5 h after injection) lagged behind hypothermia, bradycardia, or hyperglycemia (1 h after injection). I.v. infusion with a low T1AM dose (0.5 mg/kg) into nonfasted naive rats rapidly increased endogenous glucose production and plasma glucose, plasma glucagon, and corticosterone, but did not affect plasma insulin ([Klieverik *et al.* 2009](#)). Contrastingly, in i.c.v. injected (130 ng/100 g body weight (BW)) short-term fasted male mice ([Manni *et al.* 2012](#)), T1AM failed to ameliorate lipid profiles. It is known to possess a central effect, namely hypophagia, as well as peripheral effects of raised plasma glucose levels and reduced peripheral insulin sensitivity (the latter being also seen after i.p. injection ([Braulke *et al.* 2008](#), [Klieverik *et al.* 2009](#))), accompanied by pancreatic insulin production. Plasma free T_3 (fT $_3$) levels were also lowered. Nonfasted, drug-naive rats ([Klieverik *et al.* 2009](#)) treated with T1AM (100 $\mu\text{g/kg}$) acutely increased endogenous glucose production and hyperglucagonemia, while (in contrast to the effect in fasted mice ([Manni *et al.* 2012](#))) plasma insulin decreased. T0AM had a similar effect that was less profound ([Klieverik *et al.* 2009](#)). Interestingly, T1AM injection in mice resulted in 12% of the injected dose in the plasma, highlighting its systemic bioavailability ([Manni *et al.* 2012](#)). Inhibition of T1AM conversion by pretreatment with a mitochondrial amine oxidase inhibitor, clorgyline (250 $\mu\text{g}/100\text{ g BW}$), prominently

increased T1AM serum levels, but prevented the hyperglycemia and reduction of fT $_3$ levels. This led the authors to indicate that a metabolite of T1AM causes these adverse effects. Central effects of T1AM administration also included amelioration of memory and reduction in pain threshold ([Manni *et al.* 2013](#)). T1AM's enhancing effect on learning renders this compound useful in the treatment of neurodegenerative diseases.

3,3',5'-Triiodo-L-thyronine

3,3',5'- T_3 (reverse T_3 , abbreviated as rT $_3$), a product of 5-deiodination of T_4 by D1 and D3, is a potent initiator of actin polymerization in astrocytes. It portrays similar effectiveness to T_4 and much more than T_3 ([Farwell *et al.* 2006](#)). In hypothyroid rodents, neurons and astrocytes develop poor actin cytoskeletons that T_3 replacement cannot rescue. However, rT $_3$ initiates reappearance of filamentous actin within minutes without altering total actin mRNA or protein content ([Farwell *et al.* 1990](#), [Siegrist-Kaiser *et al.* 1990](#)). This rT $_3$ property is attributed to TR $\Delta\alpha 1$, a native TR isoform that lacks a nuclear localization signal and is present in the extranuclear compartment of astrocytes and neurons. This isoform has the ligand affinity and specificity required for of actin polymerization by rT $_3$. A study of the astrocytes of the developing mouse cerebellum deprived of both TRs showed that TR $\Delta\alpha 1$ rescued the actin cytoskeleton's response to rT $_3$ ([Flamant & Samarut 2003](#)). Thus, THs may require TR regions that are not necessarily canonical DNA-binding regions. rT $_3$ also inhibits free FA levels in chickens stimulated with dexamethasone or adrenaline ([Bobek *et al.* 2002](#)).

3,5-Diiodo-L-thyronine

Several studies have indicated 3,5-diiodo-L-thyronine (T_2), an endogenous metabolite of T_3 , as a peripheral mediator of several TH metabolic effects. Although conversion of T_3 to T_2 has not been demonstrated *in vitro*, indirect evidence indicates that T_2 is indeed formed from T_3 *in vivo* through deiodination ([Moreno *et al.* 2002](#)). Serum concentrations of T_2 in humans are within the picomolar range (16 pM in healthy individuals to 50 pM maximum in individuals with nonthyroidal illness; [Pinna *et al.* 1997](#)). Rat intra-hepatic T_2 concentrations are 1.5 fmol/100 mg ([Moreno *et al.* 2002](#)). To date, results in hypothyroid rats suggest that T_2 has specific actions on resting metabolic rate (RMR) that are distinct from those of T_3 : they are more rapid and not attenuated by actinomycin D (see [Fig. 1A and B](#); [Lanni *et al.* 1996](#)).

Figure 1

Changes in RMR in hypothyroid (P+I) and euthyroid (N) rats after administration of T₄, T₃, and the nonclassical thyroid hormone T₂, with or without simultaneous administration of actinomycin D. (A) Hypothyroidism was chronically induced by combined treatment of propylthiouracil (PTU) and IOP (P+I). N and P+I rats were acutely injected with 25 µg iodothyronine/100 g body weight (BW). Each data-point shows the mean $\pm$ s.e.m. from four rats. Values are expressed as a percent change from the value at time 0 (i.e. immediately before injection). Actual RMRs (lO₂ kg/0.75 per h) at time 0 were 1.01 ± 0.12 , 0.99 ± 0.10 , and 0.94 ± 0.08 for P+I+T₃, P+I+3,5-T₂, and P+I+T₄ groups respectively. (B) Actinomycin D (8 µg/100 g BW) was injected in combination with 25 µg/100 g BW of either T₃ or 3,5-T₂. Each data-point is the mean $\pm$ s.e.m. from four rats. Values are expressed as a percent change from the time 0 value (i.e. immediately before injection). Actual RMRs (lO₂/kg^{0.75}/h) at time 0 were 1.06 ± 0.15 , 0.98 ± 0.12 , and 1.44 ± 0.04 for P+I+T₃+actinomycin D, P+I+3,5-T₂+actinomycin D, and N+T₃+actinomycin D groups respectively. (C) RMRs (lO₂ kg/0.75 per h) at time 0 were 1.41 ± 0.03 , 1.39 ± 0.04 , and 1.42 ± 0.03 for N+T₃, N+3,5-T₂, and N+T₄ groups respectively. Figure adapted from [Moreno et al. \(2002\)](#), republication approved by the Endocrine Society.

T₃ injection to euthyroid animals resulted in combined T₃ and T₂ patterns on RMR (see Fig. 1C). T₃, propylthiouracil (inhibiting type 1 deiodinase and thyroid peroxidase activity), and iopanoic acid (inhibiting the activity of all three deiodinases) combined treatment showed a long-term induction of RMR. T₂ is thus predominantly responsible for short-term induction of RMR (Fig. 1A; [Moreno et al. 2002](#)). The metabolic effects of T₂ also underlined the ability of this hormone to improve survival of hypothyroid rats to cold with persistent increased energy expenditure ([Lanni et al. 1998](#)). Furthermore, upon T₂ administration to hypothyroid rats, the RMR and FA oxidation increases in the muscle mitochondria are accompanied by mitochondrial translocation of the FA transporter FAT/CD36, ensuring effective increases in metabolic rate ([Lombardi et al. 2012](#)). Several data support the ability of T₂ to stimulate mitochondrial activities in a very rapid manner ([Lanni et al. 1992, 1993, 1994](#), [Goglia 2005](#), [Cavallo et al. 2011](#)), excluding short-term genomic action of T₂. Chronic treatment of hypothyroid rats with T₂ revealed a different picture: T₂ upregulated protein levels of ATP synthase subunits (alpha, beta, F(o))I-PVP, and OSCP; [Mangiullo et al. 2010](#)). Increase in β -subunit mRNA accumulation suggested indirect transcriptional regulation by T₂ through activation of the transcription factor, GA-binding protein/nuclear respiratory factor-2 ([Mangiullo et al. 2010](#)). Moreover, D1 activity in the rat anterior pituitary has been shown to be increased transiently after a single injection of T₂, while in a reaggregate culture of anterior pituitary, T₂ has been demonstrated to stimulate D1 at 24 h after its application, dose dependently ([Baur et al. 1997](#)).

T₂, as a nonclassical TH, is able to prevent BW gain when administered i.p. to rats fed a high-fat diet without inducing T₃-related undesirable side effects (tachycardia, cardiac hyperplasia, and decreased TSH levels), at least at the administered dose (25 µg/100 g BW for 4 weeks) ([Lanni et al. 2005](#), [De Lange et al. 2011](#), [Moreno et al. 2011](#)). At this dose, by almost doubling hepatic FA oxidation rate, T₂ efficiently prevented HFD-induced i) hepatic fat accumulation, ii) insulin resistance, and iii) increase in serum triglycerides (TGs) and cholesterol levels ([Lanni et al. 2005](#)). T₂ stimulated mitochondrial uncoupling, decreased ATP synthesis, and increased fat burning, thus counteracting obesity ([Lanni et al. 2005](#)).

An important consequence of the above-described effects of T₂ included increased skeletal muscle insulin sensitivity, due to an increased response to insulin of Akt/PKB phosphorylation, and sarcolemmal glucose transporter 4 accumulation ([Moreno et al. 2011](#)). Importantly, T₂ also induced biochemical and structural shifts

toward glycolytic myofibers (Moreno *et al.* 2011). For an overview of T_2 's effects on metabolism, see Fig. 2. Proteomic analysis of intracellular and mitochondrial proteins (Silvestri *et al.* 2010) revealed that mitochondria were the principal targets of T_2 's normalizing effects on changes induced by high-fat diet (HFD). BN-page analysis revealed that T_2 partially restored individual OXPHOS complex (predominantly complexes I and II) levels induced by HFD. Additionally, T_2 augmented the activities of respiratory complexes, with respect to both HFD (except complex V) and N animals (except complex IV). In rats pre-fed a HFD, subsequent T_2 administration reduced hepatic fat and hyperlipidemia via the same biochemical pathways described previously (Mollica *et al.* 2009).

T_2 carries out its antilipidemic effects via activation of two important factors involved in lipid metabolism: AMPK and nuclear deacetylase sirtuin 1 (SIRT1). AMPK is a known sensor of cellular ATP levels (Ruderman *et al.* 2013), and SIRT1 regulates metabolic balance in response to increases in cellular NAD^+ :NADH ratios. It has recently been identified to be a crucial target abating, diet-induced obesity in rodents (Rodgers *et al.* 2005, Lagouge *et al.* 2006, Gerhart-Hines *et al.* 2007). After simultaneous administration to rats receiving a high-fat diet, rapid induction of hepatic FA oxidation by T_2 (within 6 h) was concomitant with hepatic activation of SIRT1, an activity persisting over time. Increased phosphorylation of AMPK was observed after 4 weeks of treatment (De Lange *et al.* 2011).

Figure 2

Thyroid synthesis of thyroid hormones (THs) and administration effects of nonclassical THs. Question mark, thyroid synthesis of T_2 and T1AM is currently still under debate. Peripheral synthesis of nonclassical THs by deiodinase activity (see text) is not indicated. Administration of nonclassical THs (for explanations of treatments, see text) indicated in color. White, Triac incubation in rat primary cultures; yellow, i.p. administration

of T_2 in rats on a high-fat diet; green, i.p. or i.v. administration of T1AM in mice; grey, i.v. administration of T1AM in mice; red, i.c.v. administration of T1AM to fasted mice; blue, i.c.v. administration of T1AM to mice; and purple, rT₃ administration to mice. Arrows pointing upward, upregulation; arrows pointing downward, downregulation; double horizontal arrows, no change; and absence of arrows, no effect reported to date.

Induction of SIRT1 led to deacetylation of peroxisome proliferator-activated receptor γ coactivator-1 α and sterol receptor element binding protein-1c (SREBP-1c), associated with induction and reduction of expression of genes involved in FA oxidation and lipogenesis respectively (De Lange *et al.* 2011). These findings provide a clue to explain T₂'s effectiveness in lowering hepatic fat accumulation and counteracting insulin resistance with respect to T₃. In a similar system, T₃ has increased hepatic lipogenesis (Cable *et al.* 2009).

A second clue indicating that T₂ has contrasting effects on hepatic lipogenesis involving SREBP-1c was found *in vitro*. T₃ increases an active precursor of SREBP-1c in HepG2 cells without modulating SREBP-1c transcription (Gnoni *et al.* 2012). T₂, however, blocks proteolytic cleavage and thus activation of SREBP-1c (Rochira *et al.* 2013) independent of transcription. Consequently, FA synthase expression reduced. The resulting inhibitory effect of T₂ on lipogenesis is concordant with *in vivo* findings (De Lange *et al.* 2011) and mechanistically complementary to SIRT1-dependent deacetylation of SREBP-1c (De Lange *et al.* 2011). The liver is not the only organ in which T₂ activates SIRT1: T₂ has been shown to act through SIRT1 activation in the kidney (Shang *et al.* 2013). Treatment with T₂ prevented diabetic nephropathy (DN) in a diabetic rat model via SIRT1-dependent deacetylation and p65, a subunit of nuclear factor- κ B, inactivation, thus inhibiting the inflammatory process crucial to this pathology. In rat mesangial cells, the DN phenotype was induced by exposure to high glucose, and treatment with T₂ under these conditions counteracted the DN phenotype. Co-treatment with T₂ and sirtinol – a specific SIRT1 inhibitor (Shang *et al.* 2013) – abolished deacetylation of p65. T₂ leads to dephosphorylation of JNK independent of SIRT1, and did not associate with abating the DN phenotype (Shang *et al.* 2013). Thus, SIRT1 activation plays a crucial role in T₂'s relieving effect on DN.

As a first step in projecting rodent data to study T₂'s metabolic effects in humans, two healthy volunteers were administered T₂ (1–4 μ g/kg BW) acutely. After 6 h, a significant increase in RMR was detected in both patients. Daily T₂ administration for 28 days increased RMR by $\sim$ 15% and decreased BW by about 4 kg. Ultrasonography revealed that one subject showed reductions in steatosis. Additionally, total serum cholesterol levels were lowered, and no side effects were recorded (Antonelli *et al.* 2011). A mechanism by which T₂ reduces cholesterol in the serum (Lanni *et al.* 2005, Antonelli *et al.* 2011, De Lange *et al.* 2011) was recently called into question. T₂'s LDL-lowering effects are independent of the LDL receptor (Goldberg *et al.* 2012),

as determined by feeding a western type diet to LDL receptor-deficient mice (Ldlr^{-/-}) and treating with T₂. The diet was chosen because dietary absorption of cholesterol and TG drives hepatic apoB production, especially in Ldlr^{-/-} mice. These mice develop much higher levels of cholesterol and atherosclerosis. T₂ had no effect on TG levels, probably due to increased lipolysis, but led to marked reductions in liver apoB and circulating apoB48 and apoB100 (Goldberg *et al.* 2012).

To study whether the lipid-lowering effects of T₂ were directly acting on the liver, or if they were secondary to changes in endocrine or metabolic pathways, primary rat hepatocytes, overloaded with lipids (to obtain 'fatty hepatocytes') and treated with T₂ (10⁻⁵ M) have been employed (Grasselli *et al.* 2011a). This experimental setup demonstrated that T₂ reversed the effects induced by lipid overload in these cells, thus supporting a direct effect of T₂. Moreover, rat hepatoma (FAO) cells defective for functional TRs were used to answer whether T₂-mediated lowering of hepatic lipid profiles even requires TR action (Grasselli *et al.* 2011b). Exposure to pharmacological doses of T₂ (10⁻⁵ M) for 24 h reversed the effects induced by FAs and increased mitochondrial uncoupling, thus indicating that the actions of T₂ in these cells are independent of transcriptionally functional TRs.

Intracellular action of T₂ also is described in avian cells during fetal development and cell differentiation (Incerpi *et al.* 2002). T₂ regulates DNA synthesis, cell-cycle proteins (Alisi *et al.* 2004), and several membrane-associated transport systems, whose activity is related to cell proliferation (Incerpi *et al.* 2002, 2005). T₂'s effect on the Na⁺-H⁺ exchanger was identified for 14-day- and 19-day-old cells, whereas the effect on amino acid transport was present at late stages of embryo development. Both transport systems were activated through a signal transduction pathway involving the PKC, MAPK, and PI3K pathways (Incerpi *et al.* 2002). Moreover, T₂ exerts a short-term inhibitory effect on the Na⁺-K⁺-ATPase, the magnitude of which strongly correlates to the developmental age of the isolated cells (Scapin *et al.* 2009). The Na⁺-K⁺-ATPase inhibition is mediated through the activation of PKA, PKC, and PI3K (Scapin *et al.* 2009). Signal transduction pathways contributing to the modulation of the sodium pump by T₂ are involved in the control exerted on cell proliferation.

Recently, it has been shown that T₂ exerts short-term effects on intracellular calcium concentrations and NO release by modulating plasma membrane and mitochondrial pathways in pituitary GH3 cells (Del Viscovo *et al.* 2012). In particular, T₂ facilitates physiological Ca²⁺

Table 1 Involvement of TRs or alternative receptors in non-classical thyroid hormone action

Non-classical thyroid hormone	Affinity for/transactivation through TR α or TR β	Affinity for other receptors
Triac T1AM	High (Schueler <i>et al.</i> 1990) Absent (Chiellini <i>et al.</i> 1998)	None yet identified High (trace amine-associated receptor 1 (TAAR1); Zucchi <i>et al.</i> 2006)
rT ₃ T ₂	High ^a (TR $\Delta\alpha$ 1 (native TR isoform); Flamant & Samarut 2003) Weak (human TR α ; Cioffi <i>et al.</i> 2010) Weak (human TR β ; Ball <i>et al.</i> 1997, Cioffi <i>et al.</i> 2010, De Lange <i>et al.</i> 2011, Mendoza <i>et al.</i> 2013) High (short TR β of tilapia fish; Mendoza <i>et al.</i> 2013, Navarrete-Ramirez <i>et al.</i> 2014)	None yet identified None yet identified

^aNongenomic action.

efflux from mitochondria through activation of mt-NCX by interacting with different mitochondrial complexes (Del Viscovo *et al.* 2012).

T₂'s biological effects are not restricted to mammalian species. Indeed, in the goldfish *Carassius auratus*, stimulation of pyruvate-fueled liver and muscle mitochondrial respiration was observed 5 min after 0.3 nM T₂ incubation (Leary *et al.* 1996). García *et al.* (2004) examined the effects of short-term T₄, T₃, and T₂ exposure (0.1 μ M; 12 or 24 h) on D1 and D2 activities and mRNA in killifish (tilapia) liver and showed that these hormones decreased D2 activity, the effect of T₂ being relatively more rapid. T₂ also regulates thermal acclimation in zebra fish (*Danio rerio*) with an efficiency comparable to T₃ (Little *et al.* 2013). The conserved role for T₂ on regulating metabolic efficiency in many species validates the motion to learn more about biological actions of this nonclassical TH.

Mechanism of action of T₂

Questions surrounding the cellular-molecular mechanism of action of T₂ remain. Both TR- and non TR-mediated actions may be elicited by T₂. Ball *et al.* (1997) reported that T₂ exerted selective thyromimetic effects. In the same report, T₂ showed a 60 times weaker affinity for TR β than T₃. Mendoza *et al.* (2013) reported that in teleosts, effects of T₂ may be mediated by an isoform of one of the two known TR β s, namely TR β 1 that contains a 9-amino-acid insert in its ligand-binding domain (long TR β 1), whereas T₃ binds preferentially to a short TR β 1 isoform lacking this insert. Moreover, the authors confirmed that T₂ has a weak affinity for human TR β (about 40-fold less than T₃) and a similarly weak transactivation capacity compared with T₃ (Ball *et al.* 1997, Cioffi *et al.* 2010, De Lange *et al.* 2011, Mendoza *et al.* 2013). In tilapia, both T₃ and T₂ are

important in growth, a process, however, mediated by different TR β 1 isoforms (Navarrete-Ramirez *et al.* 2014). An overview of TR or alternative receptor involvement in the action of nonclassical THs is shown in Table 1.

Non TR-mediated effects of T₂ are evident. It is known that T₂ specifically stimulates the activity of isolated cytochrome *c* oxidase (COX) from bovine heart mitochondria. T₃ barely stimulates COX. T₂ binding to COX induces conformational changes. Studies show specific binding of labeled T₂ to the subunit Va of COX from bovine heart. T₂, and to a small extent T₃, but not thyroxine and thyronine, abolished allosteric inhibition of ascorbate respiration of reconstituted COX by ATP. Inhibition is rescued by a monoclonal antibody to the subunit Va. (Goglia *et al.* 1994, Arnold *et al.* 1998). T₂ directly activates SIRT1 (De Lange *et al.* 2011), influencing downstream pathways and inducing benefits. Shang *et al.* (2013) showed that this interaction mitigates a DN by using the Sirtuin inhibitor Sirtinol.

Conclusion and perspectives

It is clear that the so-called 'nonclassical THs' can induce various biological actions. TH derivatives exert important actions on metabolic parameters and on growth. At the cellular-molecular level, several pathways are affected, the most intriguing of which are related to lipid metabolism and signaling pathways. Beneficial effects of these molecules require more considerations due to their potential to modulate human health.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review.

Funding

This work has been supported, in part, by the following grants: MIUR COFIN 2006 Prot. 2006051517 and MIUR COFIN 2008 Prot. 200895RS2X.

References

- Ackermans MT, Klieverik LP, Ringeling P, Endert E, Kalsbeek A & Fliers E 2010 An online solid-phase extraction-liquid chromatography-tandem mass spectrometry method to study the presence of thyronamines in plasma and tissue and their putative conversion from 13C6-thyroxine. *Journal of Endocrinology* **206** 327–334. (doi:10.1677/JOE-10-0060)
- Alisi A, Spagnuolo S, Napoletano S, Spaziani A & Leoni S 2004 Thyroid hormones regulate DNA-synthesis and cell-cycle proteins by activation of PKC α and p42/44 MAPK in chick embryo hepatocytes. *Journal of Cellular Physiology* **201** 259–265. (doi:10.1002/jcp.20060)
- Angelin B & Rudling M 2010 Lipid lowering with thyroid hormone and thyromimetics. *Current Opinion in Lipidology* **21** 499–506. (doi:10.1097/MOL.0b013e3283402e9c)
- Antonelli A, Fallahi P, Ferrari SM, Di Domenicantonio A, Moreno M, Lanni A & Goglia F 2011 3,5-Diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. *Journal of Biological Regulators and Homeostatic Agents* **25** 655–660.
- Anzai R, Adachi M, Sho N, Muroya K, Asakura Y & Onigata K 2012 Long-term 3,5,3'-triiodothyroacetic acid therapy in a child with hyperthyroidism caused by thyroid hormone resistance: pharmacological study and therapeutic recommendations. *Thyroid* **22** 1069–1075. (doi:10.1089/thy.2011.0450)
- Araki O, Ying H, Zhu XG, Willingham MC & Cheng SY 2009 Distinct dysregulation of lipid metabolism by unliganded thyroid hormone receptor isoforms. *Molecular Endocrinology* **23** 308–315. (doi:10.1210/me.2008-0311)
- Arnold S, Goglia F & Kadenbach B 1998 3,5-Diiodothyronine binds to subunit Va of cytochrome-c oxidase and abolishes the allosteric inhibition of respiration by ATP. *European Journal of Biochemistry* **252** 325–323. (doi:10.1046/j.1432-1327.1998.2520325.x)
- Ball SG, Sokolov J & Chin WW 1997 3,5-Diiodo-L-thyronine (T₂) has selective thyromimetic effects *in vivo* and *in vitro*. *Journal of Molecular Endocrinology* **19** 137–147. (doi:10.1677/jme.0.0190137)
- Bassett JH, Harvey CB & Williams GR 2003 Mechanisms of thyroid hormone receptor-specific nuclear and extra nuclear actions. *Molecular and Cellular Endocrinology* **213** 1–11. (doi:10.1016/j.mce.2003.10.033)
- Baur A, Bauer K, Jarry H & Koehle J 1997 3,5-Diiodo-L-thyronine stimulates type 1 5'-deiodinase activity in rat anterior pituitaries *in vivo* and in reaggregate cultures and GH3 cells *in vitro*. *Endocrinology* **138** 3242–3248. (doi:10.1210/endo.138.8.5333)
- Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S & Davis P 2005 Integrin α V β 3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. *Endocrinology* **146** 2864–2871. (doi:10.1210/en.2005-0102)
- Bianco AC 2011 Minireview: cracking the metabolic code for thyroid hormone signaling. *Endocrinology* **152** 3306–3311. (doi:10.1210/en.2011-1104)
- Bobek S, Sechman A, Niezgoda J & Jacek T 2002 Reverse 3,3',5'-triiodothyronine suppresses increase in free fatty acids in chickens elicited by dexamethasone or adrenaline. *Journal of Veterinary Medicine, A, Physiology, Pathology, Clinical Medicine* **49** 121–124. (doi:10.1046/j.1439-0442.2002.00343.x)
- Bogazzi F, Hudson LD & Nikodem VM 1994 A novel heterodimerization partner for thyroid hormone receptor. Peroxisome proliferator activated receptor. *Journal of Biological Chemistry* **269** 11683–11686.
- Bracco D, Morin O, Schutz Y, Liang H, Jequier E & Burger AG 1993 Comparison of the metabolic and endocrine effects of 3,5,3'-triiodothyroacetic acid and thyroxine. *Journal of Clinical Endocrinology and Metabolism* **77** 221–228. (doi:10.1210/jcem.77.1.8325946)
- Braulke LJ, Klingenspor M, DeBarber A, Tobias SC, Grandy DK, Scanlan TS & Heldmaier G 2008 3-Iodothyronamine: a novel hormone controlling the balance between glucose and lipid utilisation. *Journal of Comparative Physiology. B, Biochemical, Systemic, and Environmental Physiology* **178** 167–177. (doi:10.1007/s00360-007-0208-x)
- Cable EE, Finn PD, Stebbins JW, Hou J, Ito BR, van Poelje PD, Linemeyer DL & Erion MD 2009 Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist. *Hepatology* **49** 407–417.
- Cavallo A, Gnoni A, Conte E, Siculella L, Zanotti F, Papa S & Gnoni GV 2011 3,5-Diiodo-L-thyronine increases FoF1-ATP synthase activity and cardiolipin level in liver mitochondria of hypothyroid rats. *Journal of Bioenergetics and Biomembranes* **43** 349–357. (doi:10.1007/s10863-011-9366-3)
- Cheng SY, Leonard JL & Davis PJ 2010 Molecular aspects of thyroid hormone actions. *Endocrine Reviews* **31** 139–170. (doi:10.1210/er.2009-0007)
- Cheng SY 2000 Multiple mechanisms for regulation of the transcriptional activity of thyroid hormone receptors. *Reviews in Endocrine and Metabolic Disorders* **1** 9–18.
- Chiellini G, Apriletti JW, Yoshihara HA, Baxter JD, Ribeiro RC & Scanlan TS 1998 A high-affinity subtype-selective agonist ligand for the thyroid hormone receptor. *Chemistry & Biology* **5** 299–306. (doi:10.1016/S1074-5521(98)90168-5)
- Chiellini G, Frascarelli S, Ghelardoni S, Carnicelli V, Tobias SC, DeBarber A, Brogioni S, Ronca-Testoni S, Cerbai E, Grandy DK *et al.* 2007 Cardiac effects of 3-iodothyronamine: a new aminergic system modulating cardiac function. *FASEB Journal* **21** 1597–1608. (doi:10.1096/fj.06-7474com)
- Cioffi F, Zambad SP, Chhipa L, Senese R, Busiello RA, Tuli D, Munshi S, Moreno M, Lombardi A, Gupta RC *et al.* 2010 TRC150094, a novel functional analog of iodothyronines, reduces adiposity by increasing energy expenditure and fatty acid oxidation in rats receiving a high-fat diet. *FASEB Journal* **24** 3451–3461. (doi:10.1096/fj.10-157115)
- Cioffi F, Senese R, Lanni A & Goglia F 2013 Thyroid hormones and mitochondria: with a brief look at derivatives and analogues. *Molecular and Cellular Endocrinology* **379** 51–61. (doi:10.1016/j.mce.2013.06.006)
- Cody V, Davis PJ & Davis FB 2007 Molecular modeling of the thyroid hormone interactions with α v β 3 integrin. *Steroids* **72** 165–170. (doi:10.1016/j.steroids.2006.11.008)
- DeBarber AE, Geraci T, Colasurdo VP, Hackenmueller SA & Scanlan TS 2008 Validation of a liquid chromatography-tandem mass spectrometry method to enable quantification of 3-iodothyronamine from serum. *Journal of Chromatography. A* **1210** 55–59. (doi:10.1016/j.chroma.2008.09.022)
- De Lange P, Senese R, Cioffi F, Moreno M, Lombardi A, Silvestri E, Goglia F & Lanni A 2008 Rapid activation by 3,5,3'-L-triiodothyronine of adenosine 5'-monophosphate-activated protein kinase/acetyl-coenzyme A carboxylase and akt/protein kinase B signaling pathways: relation to changes in fuel metabolism and myosin heavy-chain protein content in rat gastrocnemius muscle *in vivo*. *Endocrinology* **149** 6462–6470. (doi:10.1210/en.2008-0202)
- De Lange P, Cioffi F, Senese R, Moreno M, Lombardi A, Silvestri E, De Matteis R, Lionetti L, Mollica MP, Goglia F *et al.* 2011 Nonthyrotoxic prevention of diet-induced insulin resistance by 3,5-diiodo-L-thyronine in rats. *Diabetes* **60** 2730–2739. (doi:10.2337/db11-0207)
- Del Viscovo A, Secondo A, Esposito A, Goglia F, Moreno M & Canzoniero LM 2012 Intracellular and plasma membrane-initiated pathways involved in the [Ca²⁺]_i elevations induced by iodothyronines (T₃ and T₂) in pituitary GH3 cells. *American Journal of Physiology. Endocrinology and Metabolism* **302** E1419–E1430. (doi:10.1152/ajpendo.00389.2011)
- Dumas P, Autissier N, Loireau A & Michel R 1982 Effects of 3,5,3'-triiodothyroacetic acid (TRIAc) on protein metabolism of genetically obese or non-obese Zucker rats. *Comptes Rendus des Séances de la Société de Biologie et de Ses Filiales* **176** 178–183.

- Farwell AP, Lynch RM, Okulicz WC, Comi AM & Leonard JL 1990 The actin cytoskeleton mediates the hormonally regulated translocation of type II iodothyronine 5'-deiodinase in astrocytes. *Journal of Biological Chemistry* **265** 18546–18553.
- Farwell AP, Dubord-Tomasetti SA, Pietrzykowski AZ & Leonard JL 2006 Dynamic nongenomic actions of thyroid hormone in the developing rat brain. *Endocrinology* **147** 2567–2574. (doi:10.1210/en.2005-1272)
- Flamant F & Samarut J 2003 Thyroid hormone receptors: lessons from knockout and knock-in mutant mice. *Trends in Endocrinology and Metabolism* **14** 85–90. (doi:10.1016/S1043-2760(02)00043-7)
- Forman BM, Casanova J, Raaka BM, Ghysdael J & Samuels HH 1992 Half-site spacing and orientation determines whether thyroid hormone and retinoic acid receptors and related factors bind to DNA response elements as monomers, homodimers, or heterodimers. *Molecular Endocrinology* **6** 429–442. (doi:10.1210/mend.6.3.1316541)
- Frascarelli S, Ghelardoni S, Chiellini G, Vargiu R, Ronca-Testoni S, Scanlan TS, Grandy DK & Zucchi R 2008 Cardiac effects of trace amines: pharmacological characterization of trace amine associated receptors. *European Journal of Pharmacology* **587** 231–236. (doi:10.1016/j.ejphar.2008.03.055)
- Galo MG, Uñates LE & Fariás RN 1981 Effect of membrane fatty acid composition on the action of thyroid hormone on $(Ca^{2+} + Mg^{2+})$ -adenosine triphosphatase from rat erythrocyte. *Journal of Biological Chemistry* **256** 7113–7114.
- García GC, Jezierski MC, Valverde RC & Orozco A 2004 Effects of iodothyronines on the hepatic outer-ring deiodinating pathway in killifish. *General and Comparative Endocrinology* **135** 201–209. (doi:10.1016/j.ygcen.2003.09.010)
- Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, Alt FW, Wu Z & Puigserver P 2007 Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1 α . *EMBO Journal* **26** 1913–1923.
- Gnoni GV, Rochira A, Leone A, Damiano F, Marsigliante S & Siculella L 2012 3,5,3'-triiodo-L-thyronine induces SREBP-1 expression by nongenomic actions in human HEP G2 cells. *Journal of Cellular Physiology* **227** 2388–2397.
- Goglia F 2005 Biological effects of 3,5-diiodothyronine (T_2). *Biochemistry* **70** 164–172.
- Goglia F, Lanni A, Barth J & Kadenbach B 1994 Interaction of diiodothyronines with isolated cytochrome c oxidase. *FEBS Letters* **346** 295–298. (doi:10.1016/0014-5793(94)00476-5)
- Goldberg IJ, Huang LS, Huggins LA, Yu S, Nagareddy PR, Scanlan TS & Ehrenkranz JR 2012 Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway. *Endocrinology* **153** 5143–5149. (doi:10.1210/en.2012-1572)
- Grasselli E, Voci A, Canesi L, De Matteis R, Goglia F, Cioffi F, Fugassa E, Gallo G & Vergani L 2011a Direct effects of iodothyronines on excess fat storage in rat hepatocytes. *Journal of Hepatology* **54** 1230–1236. (doi:10.1016/j.jhep.2010.09.027)
- Grasselli E, Voci A, Canesi L, Goglia F, Ravera S, Panfoli I, Gallo G & Vergani L 2011b Non-receptor-mediated actions are responsible for the lipid-lowering effects of iodothyronines in FaO rat hepatoma cells. *Journal of Endocrinology* **21** 59–69. (doi:10.1530/JOE-11-0074)
- Gullberg H, Rudling M, Forrest D, Angelin B & Vennstrom B 2000 Thyroid hormone receptor β -deficient mice show complete loss of the normal cholesterol 7 α -hydroxylase (CYP7A) response to thyroid hormone but display enhanced resistance to dietary cholesterol. *Molecular Endocrinology* **14** 1739–1749. (doi:10.1210/mend.14.11.0548)
- Gullberg H, Rudling M, Salto C, Forrest D, Angelin B & Vennstrom B 2002 Requirement for thyroid hormone receptor β in T_3 regulation of cholesterol metabolism in mice. *Molecular Endocrinology* **16** 1767–1777. (doi:10.1210/me.2002-0009)
- Hackenmueller SA, Marchini M, Saba A, Zucchi R & Scanlan TS 2012 Biosynthesis of 3 iodothyronamine (T1AM) is dependent on the sodium-iodide symporter and thyroperoxidase but does not involve extrathyroidal metabolism of T_4 . *Endocrinology* **153** 5659–5667. (doi:10.1210/en.2012-1254)
- Hart ME, Suchland KL, Miyakawa M, Bunzow JR, Grandy DK & Scanlan TS 2006 Trace amine-associated receptor agonists; synthesis and evaluation of thyronamines and related analogues. *Journal of Medicinal Chemistry* **49** 1101–1112. (doi:10.1021/jm0505718)
- Hoefig CS, Köhrle J, Brabant G, Dixit K, Yap J, Strasburger CJ & Wu Z 2011 Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. *Journal of Clinical Endocrinology and Metabolism* **98** 1864–1872. (doi:10.1210/jc.2010-2680)
- Hoefig CS, Renko K, Piehl S, Scanlan TS, Bertoldi M, Opladen T, Hoffmann GF, Klein J, Blankenstein O, Sc weizer U et al. 2012 Does the aromatic L-amino acid decarboxylase contribute to thyronamine biosynthesis? *Molecular and Cellular Endocrinology* **349** 195–201. (doi:10.1016/j.mce.2011.10.024)
- Horn S, Kersseboom S, Mayerl S, Müller J, Groba C, Trajkovic-Arsic M, Ackermann T, Visser TJ & Heuer H 2013 Tetrac can replace thyroid hormone during brain development in mouse mutants deficient in the thyroid hormone transporter mct8. *Endocrinology* **154** 968–979. (doi:10.1210/en.2012-1628)
- Ianculescu AG, Giacomini KM & Scanlan TS 2009 Identification and characterization of 3-iodothyronamine intracellular transport. *Endocrinology* **150** 1991–1999. (doi:10.1210/en.2008-1339)
- Ianculescu AG, Friesema EC, Visser TJ, Giacomini KM & Scanlan TS 2010 Transport of thyroid hormones is selectively inhibited by 3-iodothyronamine. *Molecular BioSystems* **6** 1403–1410. (doi:10.1039/b926588k)
- Incerpi S, De Vito P, Luly P, Spagnuolo S & Leoni S 2002 Short-term effects of thyroid hormones and 3,5-diiodothyronine on membrane transport systems in chick embryo hepatocytes. *Endocrinology* **143** 1660–1668. (doi:10.1210/endo.143.5.8767)
- Incerpi S, Scapin S, D'Arezzo S, Spagnuolo S & Leoni S 2005 Short-term effects of thyroid hormone in prenatal development and cell differentiation. *Steroids* **70** 434–443. (doi:10.1016/j.steroids.2005.02.009)
- Irrcher I, Walkinshaw DR, Sheehan TE & Hood DA 2008 Thyroid hormone (T_3) rapidly activates p38 and AMPK in skeletal muscle *in vivo*. *Journal of Applied Physiology* **104** 178–185. (doi:10.1152/jappphysiol.00643.2007)
- Johansson L, Rudling M, Scanlan TS, Lundasen T, Webb P, Baxter J, Angelin B & Parini P 2005 Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. *PNAS* **102** 10297–10302. (doi:10.1073/pnas.0504379102)
- Klieverik LP, Foppen E, Ackermans MT, Serlie MJ, Sauerwein HP, Scanlan TS, Grandy DK, Fliers E & Kalsbeek A 2009 Central effects of thyronamines on glucose metabolism in rats. *Journal of Endocrinology* **201** 377–386. (doi:10.1677/JOE-09-0043)
- Kunitake JM, Hartman N, Henson LC, Lieberman J, Williams DE, Wong M & Hershsman JM 1989 3,5,3'-Triiodothyroacetic acid therapy for thyroid hormone resistance. *Journal of Clinical Endocrinology and Metabolism* **69** 461–466. (doi:10.1210/jcem-69-2-461)
- Ladenson PW 2011 Thyroid hormone analogues: ready for prime time. *Thyroid* **21** 101–102. (doi:10.1089/thy.2010.2100.com1)
- Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussan F, Messadeq N, Milne J, Lambert P, Elliot P et al. 2006 Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1 α . *Cell* **127** 1109–1122.
- Lanni A, Moreno M, Cioffi M & Goglia F 1992 Effect of 3,3'-diiodothyronine and 3,5-diiodothyronine on rat liver oxidative capacity. *Molecular and Cellular Endocrinology* **86** 143–148. (doi:10.1016/0303-7207(92)90138-V)
- Lanni A, Moreno M, Cioffi M & Goglia F 1993 Effect of 3,3'-diiodothyronine and 3,5-diiodothyronine on rat liver mitochondria. *Journal of Endocrinology* **136** 59–64. (doi:10.1677/joe.0.1360059)

- Lanni A, Moreno M, Horst C, Lombardi A & Goglia F 1994 Specific binding sites for 3,3'-diiodo-L-thyronine (3,3'-T₂) in rat liver mitochondria. *FEBS Letters* **351** 237–240. (doi:10.1016/0014-5793(94)00840-X)
- Lanni A, Moreno M, Lombardi A & Goglia F 1996 Calorigenic effect of diiodothyronines in the rat. *Journal of Physiology* **494** 831–837.
- Lanni A, Moreno M, Lombardi A & Goglia F 1998 3,5-Diiodo-L-thyronine and 3,5,3'-triiodo-L-thyronine both improve the cold tolerance of hypothyroid rats, but possibly via different mechanisms. *Pflügers Archiv: European Journal of Physiology* **436** 407–414. (doi:10.1007/s004240050650)
- Lanni A, Moreno M, Lombardi A, de Lange P, Silvestri E, Ragni M, Farina P, Chieffi Baccari G, Fallahi P, Antonelli A *et al.* 2005 3,5-Diiodo-L-thyronine powerfully reduces adiposity in rats by increasing the burning of fats. *FASEB Journal* **19** 1552–1554.
- Leary SC, Barton KN & Ballantyne JS 1996 Direct effects of 3,5,3'-triiodothyronine and 3,5-diiodothyronine on mitochondrial metabolism in the goldfish *Carassius auratus*. *General and Comparative Endocrinology* **104** 61–66. (doi:10.1006/gcen.1996.0141)
- Lerman J 1956 The activity of di-tribromthyronine. *Journal of Clinical Endocrinology and Metabolism* **16** 1395–1397. (doi:10.1210/jcem-16-10-1395)
- Lin HY, Sun M, Lin C, Tang HY, London D, Shih A, Davis FB & Davis PJ 2009a Androgen induced human breast cancer cell proliferation is mediated by discrete mechanisms in estrogen receptor- α -positive and -negative breast cancer cells. *Journal of Steroid Biochemistry and Molecular Biology* **113** 182–188. (doi:10.1016/j.jsbmb.2008.12.010)
- Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, Incerpi S, Drusano GL, Davis FB & Davis PJ 2009b L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. *American Journal of Physiology. Cell Physiology* **296** C980–C991. (doi:10.1152/ajpcell.00305.2008)
- Little AG, Kunisue T, Kannan K & Seebacher F 2013 Thyroid hormone actions are temperature-specific and regulate thermal acclimation in zebrafish (*Danio rerio*). *BMC Biology* **26** 11–26. (doi:10.1186/1741-7007-11-26)
- Lombardi A, De Matteis R, Moreno M, Napolitano L, Busiello RA, Senese R, de Lange P, Lanni A & Goglia F 2012 Responses of skeletal muscle lipid metabolism in rat gastrocnemius to hypothyroidism and iodothyronine administration: a putative role for FAT/CD36. *American Journal of Physiology. Endocrinology and Metabolism* **303** E1222–E1233. (doi:10.1152/ajpendo.00037.2012)
- Luongo C, Trivisano L, Alfano F & Salvatore D 2013 Type 3 deiodinase and consumptive hypothyroidism: a common mechanism for a rare disease. *Frontiers in Endocrinology* **115** 1–7. (doi:10.3389/fendo.2013.00115)
- Maia AL, Goemann IM, Meyer EL & Wajner SM 2011 Deiodinases: the balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology and disease. *Journal of Endocrinology* **209** 283–297. (doi:10.1530/JOE-10-0481)
- Mangiullo R, Gnoni A, Damiano F, Siculella L, Zanolli F, Papa S & Gnoni GV 2010 3,5-Diiodo-L-thyronine upregulates rat-liver mitochondrial F₁F₀-ATP synthase by GA-binding protein/nuclear respiratory factor-2. *Biochimica et Biophysica Acta* **1797** 233–240. (doi:10.1016/j.bbabo.2009.10.009)
- Manni ME, De Siena G, Saba A, Marchini M, Dicembrini I, Bigagli E, Cinci L, Lodovici M, Chiellini MG, Zucchi R *et al.* 2012 3-Iodothyronamine: a modulator of the hypothalamus–pancreas–thyroid axes in mice. *British Journal of Pharmacology* **166** 650–658. (doi:10.1111/j.1476-5381.2011.01823.x)
- Manni ME, De Siena G, Saba A, Marchini M, Landucci E, Gerace E, Zazzeri M, Mussili C, Pellegrini-Giampietro D, Matucci R *et al.* 2013 Pharmacological effects of 3-iodothyronamine (TIAM) in mice include facilitation and memory acquisition and retention and reduction of pain threshold. *British Journal of Pharmacology* **168** 354–362. (doi:10.1111/j.1476-5381.2012.02137.x)
- Medina-Gomez G, Hernandez A, Calvo RM, Martin E & Obregon MJ 2003 Potent thermogenic action of triiodothyroacetic acid in brown adipocytes. *Cellular and Molecular Life Sciences* **60** 1957–1967. (doi:10.1007/s00018-003-3158-9)
- Medina-Gomez G, Calvo MR & Obregon MJ 2004 T₃ and Triac inhibit leptin secretion and expression in brown and white rat adipocytes. *Biochimica et Biophysica Acta* **1682** 38–47. (doi:10.1016/j.bbalip.2004.01.007)
- Mendoza A, Navarrete-Ramirez P, Hernández-Puga G, Villalobos P, Holzer G, Renaud JP, Laudet V & Orozco A 2013 3,5-T₂ is an alternative ligand for the thyroid hormone receptor β 1. *Endocrinology* **154** 2948–2958. (doi:10.1210/en.2013-1030)
- Moeller LC & Broecker-Preuss M 2011 Transcriptional regulation by nonclassical action of thyroid hormone. *Thyroid Research* **4**(Suppl 1) S6. (doi:10.1186/1756-6614-4-S1-S6)
- Moeller LC, Dumitrescu AM & Refetoff S 2005 Cytosolic action of thyroid hormone leads to induction of hypoxia-inducible factor-1 and glycolytic genes. *Molecular Endocrinology* **19** 2955–2963. (doi:10.1210/me.2004-0542)
- Mollica MP, Lionetti L, Moreno M, Lombardi A, de Lange P, Antonelli A, Lanni A, Cavaliere G, Barletta A & Goglia F 2009 3,5-Diiodo-L-thyronine, by modulating mitochondrial functions, reverses hepatic fat accumulation in rats fed a high-fat diet. *Journal of Hepatology* **51** 363–370. (doi:10.1016/j.jhep.2009.03.023)
- Moreno M, Kaptein E, Goglia F & Visser TJ 1994 Rapid glucuronidation of tri- and tetraiodothyroacetic acid to ester glucuronides in human liver and to ether glucuronides in rat liver. *Endocrinology* **135** 1004–1009. (doi:10.1210/endo.135.3.8070342)
- Moreno M, Lombardi A, Beneduce L, Silvestri E, Pinna G, Goglia F & Lanni A 2002 Are the effects of T₃ on resting metabolic rate in euthyroid rats entirely caused by T₃ itself? *Endocrinology* **143** 504–510. (doi:10.1210/endo.143.2.8613)
- Moreno M, Silvestri E, De Matteis R, de Lange P, Lombardi A, Glinni D, Senese R, Cioffi F, Salzano AM, Scaloni A *et al.* 2011 3,5-Diiodo-L-thyronine prevents high-fat-diet-induced insulin resistance in rat skeletal muscle through metabolic and structural adaptations. *FASEB Journal* **25** 3312–3324. (doi:10.1096/fj.11-181982)
- Navarrete-Ramirez P, Luna M, Valverde RC & Orozco A 2014 3,5-T₂ stimulates tilapia growth through an alternate isoform of thyroid hormone receptor β 1. *Journal of Molecular Endocrinology* **52** 1–9. (doi:10.1530/JME-13-0145)
- Oetting A & Yen PM 2007 New insights into thyroid hormone action. *Best Practice & Research. Clinical Endocrinology & Metabolism* **21** 193–208. (doi:10.1016/j.beem.2007.04.004)
- Orozco A, Valverde RC, Olvera A & García GC 2012 Iodothyronine deiodinases: a functional and evolutionary perspective. *Journal of Endocrinology* **215** 207–219. (doi:10.1530/JOE-12-0258)
- Pascual A & Aranda A 2013 Thyroid hormone receptors, cell growth and differentiation. *Biochimica et Biophysica Acta* **1830** 3908–3916. (doi:10.1016/j.bbagen.2012.03.012)
- Piehl S, Heberer T, Balizs G, Scanlan TS, Smits R, Koks B & Köhrle J 2008 Thyronamines are isozyme-specific substrates of deiodinases. *Endocrinology* **149** 3037–3045. (doi:10.1210/en.2007-1678)
- Pinna G, Meinhold H, Hiedra L, Thoma R, Hoell T, Gräf KJ, Stoltzenburg-Diding G, Eravci M, Prengel H, Brödel O *et al.* 1997 Elevated 3,5-diiodothyronine concentrations in the sera of patients with nonthyroidal illnesses and brain tumors. *Journal of Clinical Endocrinology and Metabolism* **82** 1535–1542. (doi:10.1210/jcem.82.5.3939)
- Pittman CS, Shimizu T, Burger A & Chambers JB Jr 1980 The nondeiodinative pathways of thyroxine metabolism: 3,5,3',5'-tetraiodothyroacetic acid turnover in normal and fasting human subjects. *Journal of Clinical Endocrinology and Metabolism* **50** 712–716. (doi:10.1210/jcem-50-4-712)
- Pramfalk C, Pedrelli M & Parini P 2011 Role of thyroid receptor β in lipid metabolism. *Biochimica et Biophysica Acta* **1812** 929–937. (doi:10.1016/j.bbadis.2010.12.019)

- Rochira A, Damiano F, Marsigliante S, Gnoni GV & Siculella L 2013 3,5-Diiodo-L-thyronine induces SREBP-1 proteolytic cleavage block and apoptosis in human hepatoma (HepG2) cells. *Biochimica et Biophysica Acta* **1831** 1679–1688.
- Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM & Puigserver P 2005 Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. *Nature* **434** 113–118.
- Ruderman NB, Carling D, Prentki M & Cacicedo 2013 AMPK, insulin resistance, and the metabolic syndrome. *Journal of Clinical Investigation* **123** 2764–2772.
- Saba A, Chiellini G, Frascarelli S, Marchini M, Chelardoni S, Rafaelli A, Tonacchera M, Vitti P, Scanlan TS & Zucchi R 2010 Tissue distribution and cardiac metabolism of 3-iodothyronamine. *Endocrinology* **151** 5063–5073. (doi:10.1210/en.2010-0491)
- Scanlan TS, Suchland KL, Hart ME, Chiellini G, Huang Y, Kruzich PJ, Frascarelli S, Crossley DA, Bunzow JR, Ronca-Testoni S *et al.* 2004 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. *Nature Medicine* **10** 638–642. (doi:10.1038/nm1051)
- Scapin S, Leoni S, Spagnuolo S, Fiore AM & Incerpi S 2009 Short-term effects of thyroid hormones on Na⁺–K⁺–ATPase activity of chick embryo hepatocytes during development: focus on signal transduction. *American Journal of Physiology. Cell Physiology* **296** C4–C12. (doi:10.1152/ajpcell.90604.2007)
- Schueler PA, Schwartz HL, Strait KA, Mariash CN & Oppenheimer JH 1990 Binding of 3,5,3'-triiodothyronine (T₃) and its analogs to the *in vitro* translational products of c-erbA protooncogenes: differences in the affinity of the α - and β -forms for the acetic acid analog and failure of the human testis and kidney α -2 products to bind T₃. *Molecular Endocrinology* **4** 227–234. (doi:10.1210/mend-4-2-227)
- Shang G, Gao P, Zhao Z, Chen Q, Jiang T, Zhang N & Li H 2013 3,5-Diiodo-L-thyronine ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats. *Biochimica et Biophysica Acta* **1832** 674–684.
- Sherman SI & Ladenson PW 1992 Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic, not pituitary, superagonist effects. *Journal of Clinical Endocrinology and Metabolism* **75** 901–905. (doi:10.1210/jcem.75.3.1517383)
- Shoemaker TJ, Kono T, Mariash CN & Evans-Molina C 2012 Thyroid hormone analogues for the treatment of metabolic disorders: new potential for unmet clinical needs? *Endocrine Practice* **18** 954–964. (doi:10.4158/EP12086.RA)
- Siegrist-Kaiser C & Burger AG 1994 Modification of the side chain of thyroid hormones. In *Thyroid Hormone Metabolism*, pp 17–198. Eds SY Wu & TJ Visser TJ. Boca Raton: CRC Press, Inc.
- Siegrist-Kaiser CA, Juge-Aubry C, Tranter MP, Ekenbarger DM & Leonard JL 1990 Thyroxine-dependent modulation of actin polymerization in cultured astrocytes. A novel, extranuclear action of thyroid hormone. *Journal of Biological Chemistry* **265** 5296–5302.
- Silvestri E, Cioffi F, Glinni D, Ceccarelli M, Lombardi A, de Lange P, Chambery A, Severino V, Lanni A, Goglia F *et al.* 2010 Pathways affected by 3,5-diiodo-L-thyronine in liver of high fat-fed rats: evidence from two-dimensional electrophoresis, blue-native PAGE, and mass spectrometry. *Molecular BioSystems* **6** 2256–2271. (doi:10.1039/c0mb00040j)
- Snead AN, Miyakawa M, Tan ES & Scanlan TS 2008 Trace amine-associated receptor 1 (TAAR1) is activated by amiodarone metabolites. *Bioorganic & Medicinal Chemistry Letters* **18** 5920–5922. (doi:10.1016/j.bmcl.2008.08.013)
- Tan ES, Miyakawa M, Bunzow JR, Grandy DK & Scanlan TS 2007 Exploring the structure–activity relationship of the ethylamine portion of 3-iodothyronamine for rat and mouse trace amine-associated receptor 1. *Journal of Medicinal Chemistry* **50** 2787–2798. (doi:10.1021/jm0700417)
- Tan ES, Groban ES, Jacobson MP & Scanlan TS 2008 Toward deciphering the code to aminergic G protein-coupled receptor drug design. *Chemistry & Biology* **15** 343–353. (doi:10.1016/j.chembiol.2008.03.004)
- Tata JR 2013 The road to nuclear receptors of thyroid hormone. *Biochimica et Biophysica Acta* **1830** 3860–3866.
- Visser TJ 1990 Importance of deiodination and conjugation in the hepatic metabolism of thyroid hormone. In *The Thyroid Gland*, pp 255–283. Ed. MA Greer. New York: Raven Press.
- Visser TJ 2013 Thyroid hormone transporters and resistance. *Endocrine Development* **24** 1–10. (doi:10.1159/000343695)
- Webb P 2010 Thyroid hormone receptor and lipid regulation. *Current Opinion in Investigational Drugs* **11** 1135–1142.
- Weitzel JM & Alexander Iwen K 2011 Coordination of mitochondrial biogenesis by thyroid hormone. *Molecular and Cellular Endocrinology* **342** 1–7. (doi:10.1016/j.mce.2011.05.009)
- Williams GR 2000 Cloning and characterization of two novel thyroid hormone receptor β isoforms. *Molecular and Cellular Biology* **20** 8329–8342. (doi:10.1128/MCB.20.22.8329-8342.2000)
- Wrutniak C, Cassar-Malek I, Marchal S, Rascle A, Heusser S, Keller JM, Fléchon J, Dauça M, Samarut J, Ghysdæl J *et al.* 1995 A 43-kDa protein related to c-Erb A α 1 is located in the mitochondrial matrix of rat liver. *Journal of Biological Chemistry* **270** 16347–16354. (doi:10.1074/jbc.270.27.16347)
- Wrutniak-Cabello C, Casas F & Cabello G 2001 Thyroid hormone action in mitochondria. *Journal of Molecular Endocrinology* **26** 67–77. (doi:10.1677/jme.0.0260067)
- Zucchi R, Chiellini G, Scanlan TS & Grandy DK 2006 Trace amine-associated receptors and their ligands. *British Journal of Pharmacology* **149** 967–978. (doi:10.1038/sj.bjp.0706948)

Received in final form 13 January 2014

Accepted 21 January 2014

Accepted Preprint published online 24 January 2014